Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
December 2025
Predictors of damage accrual by organ domain in systemic lupus erythematosus
Rheumatology 2025;18:keaf610 Doi: 10.1093/rheumatology/keaf610 Epub ahead of print
Kandane-Rathnayake et al. reported that risk factors for individual organ system damage were highly varied in patients with SLE, and not all factors associated with domain-specific damage were captured by summed systemic lupus international collaborating clinics/american college of rheumatology damage index (SLICC/ACR SDI) for overall organ damage.
June 2025
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial
Lupus Sci Med. 2025;12(1):e001517
Patient-reported outcomes from the deucravacitinib, 48-week, phase II, PAISLEY study show that patients with SLE experienced greater improvements in pain, fatigue and health-related quality-of-life scores at Week 48 with deucravacitinib versus placebo treatment.